AGC Biologics, a global contract development and manufacturing organization based in Seattle, announced a new partnership with BioConnection, a specialized contract manufacturing organization, to provide end-to-end pharmaceutical development and manufacturing capabilities for drug substance and product.
According to Patricio Massera, CEO of AGC Biologics, “Now more than ever global pharmaceutical companies and developers need reliable facilities to produce and fill their drug products, and by combining our resources with BioConnection we are offering a new end-to-end solution for them under one contract with AGC Biologics. We believe BioConnection has a strong acumen, and this established partnership will enhance our biopharmaceutical manufacturing offering by providing drug product services for protein biologics, allowing us to create deeper relationships with developers to help get their products to patients in need.”